Avita Medical Inc. has announced data from 19 scientific abstracts, including 14 podium presentations, at the 2026 Boswick Burn & Wound Symposium. The presentations included the first surgeon-reported integrated use of all three AVITA Medical technologies—RECELL, PermeaDerm, and Cohealyx—in individual patient cases. Clinical and tissue-level findings from separate studies evaluating PermeaDerm and Cohealyx were also presented, with initial findings from multicenter clinical trials discussed and full study results expected in 2026. Data presented showed that PermeaDerm supported early blood vessel growth and organized tissue formation without increased inflammation. RECELL analyses demonstrated consistent trends in improved healing, reduced complications, and shorter hospital stays across studies and real-world registry data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avita Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9642066-en) on January 25, 2026, and is solely responsible for the information contained therein.